Compare OII & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OII | SYRE |
|---|---|---|
| Founded | 1964 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | N/A | 2016 |
| Metric | OII | SYRE |
|---|---|---|
| Price | $23.30 | $33.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $25.00 | ★ $56.50 |
| AVG Volume (30 Days) | 742.2K | ★ 744.8K |
| Earning Date | 10-22-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.60 | N/A |
| EPS | ★ 2.29 | N/A |
| Revenue | ★ $2,829,032,000.00 | N/A |
| Revenue This Year | $5.93 | N/A |
| Revenue Next Year | $0.78 | N/A |
| P/E Ratio | $10.50 | ★ N/A |
| Revenue Growth | ★ 8.71 | N/A |
| 52 Week Low | $15.46 | $10.91 |
| 52 Week High | $28.31 | $35.31 |
| Indicator | OII | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 67.93 |
| Support Level | $26.76 | $32.26 |
| Resistance Level | $27.64 | $34.32 |
| Average True Range (ATR) | 0.91 | 1.80 |
| MACD | -0.37 | -0.18 |
| Stochastic Oscillator | 0.67 | 75.52 |
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.